SCHEMBL5713495

SCHEMBL5713495

CC1CCCN(C(CCCc2ccccc2)CCOCCC(CCCc2ccccc2)N2CCCC(C)C2)C1

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
HRH3 Q9Y5N1 6/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
RAB9A P51151 1/20 0.43
KDM4E B2RXH2 1/20 0.42
SIGMAR1 Q99720 3/20 0.41
MC4R P32245 1/20 0.41
GAA P10253 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
DRD2 P14416 1/20 0.39
HTR2A P28223 1/20 0.39
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5713440 0.86 SIGMAR1 (0.50) HRH3NPC1ALDH1A1RAB9ASIGMAR1
SCHEMBL5713432 0.85 SIGMAR1 (0.42) SMN1; SMN2HRH3ALDH1A1SIGMAR1MC4R
SCHEMBL5713501 0.85 SIGMAR1 (0.42) SMN1; SMN2HRH3ALDH1A1SIGMAR1MC4R
SCHEMBL5713520 0.84 HRH3 (0.52) SMN1; SMN2HRH3ALDH1A1RAB9ASIGMAR1
SCHEMBL5713485 0.83 HRH3 (0.55) SMN1; SMN2HRH3ALDH1A1RAB9ASIGMAR1
SCHEMBL6566709 0.77 HRH3 (0.46) SMN1; SMN2HRH3ALDH1A1KDM4ESIGMAR1
SCHEMBL6570120 0.77 L3MBTL1 (0.47) HPGDSMN1; SMN2L3MBTL1NPC1ALDH1A1
SCHEMBL491602 0.76 HRH3 (0.68) HRH3ALDH1A1KDM4E
SCHEMBL1335893 0.72 SMN1; SMN2 (0.41) SMN1; SMN2HRH3L3MBTL1SIGMAR1GAA
SCHEMBL1335891 0.72 SMN1; SMN2 (0.41) SMN1; SMN2HRH3L3MBTL1SIGMAR1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1863487-B1 TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS BIOPROJET SOC CIV (FR) 2013-05-29 EP claimed
CN-101171009-A Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands BIOPROJET SOC CIV (FR) 2008-04-30 CN claimed
EP-1428820-B1 Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications BIOPROJET SOC CIV (FR) 2006-05-17 EP claimed
EP-1100503-B1 NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS ILE BIOPROJET SOC CIV (FR) 2004-09-22 EP claimed
CN-101171009-B Use of non-imidazole alkylamines histamine h3- receptor ligands in treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia BIOPROJET SOC CIV 2012-11-07 CN disclosed
CN-101171009-A Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine h3- receptor ligands BIOPROJET SOC CIV (FR) 2008-04-30 CN disclosed